Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates

Bibliographic Details
Title: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates
Authors: Yu-Ying Shi, Gang Fan, Ruirong Tan, Shan Li, Hua-Bing Sun, Rui Li, Mengni Yang, Shanshan Gao, Miao Liu, Meng-Yuan Dai
Source: Cell Death and Disease, Vol 15, Iss 9, Pp 1-13 (2024)
Publisher Information: Nature Publishing Group, 2024.
Publication Year: 2024
Collection: LCC:Cytology
Subject Terms: Cytology, QH573-671
More Details: Abstract The current selection of ligands for both proteins of interest (POI) and E3 ubiquitin ligase significantly restricts the scope of targeted protein degradation (TPD) technologies. This study introduces cell-penetrating peptide-induced chimera conjugates (cp-PCCs) targeting the DHHC3 enzyme involved in PD-L1 palmitoylation. This approach disrupts PD-L1’s immunosuppressive function, enhancing anti-tumor immunity. We developed cp-PCCs to degrade DHHC3, directly linking DHHC3-mediated PD-L1 palmitoylation to PD-L1 stability on tumor cells. Our research utilized both in vitro assays and in vivo experiments in immune checkpoint blockade-resistant mouse models. We focused on a CRBN-based cp-PCC named PCC16, which demonstrated a DC50 of 102 nmol for DHHC3 degradation and significantly reduced PD-L1 levels. In resistant models, PCC16 not only robustly downregulated PD-L1 but also exhibited substantial anti-tumor activity in vivo without significant toxicity. This outperformed traditional inhibitors, showcasing the potential of cp-PCC technology to bypass current PROTAC limitations. Our findings suggest that cp-PCCs offer a promising method for targeting PD-L1 through DHHC3 inhibition and support their continued exploration as a versatile tool in cancer immunotherapy, especially for tumors resistant to standard treatments.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2041-4889
Relation: https://doaj.org/toc/2041-4889
DOI: 10.1038/s41419-024-07073-y
Access URL: https://doaj.org/article/aac14e898bd84fae9a32372bac3d450d
Accession Number: edsdoj.14e898bd84fae9a32372bac3d450d
Database: Directory of Open Access Journals
More Details
ISSN:20414889
DOI:10.1038/s41419-024-07073-y
Published in:Cell Death and Disease
Language:English